Portage Biotech Inc. Files August 2024 6-K Report

Ticker: ATON · Form: 6-K · Filed: Aug 13, 2024 · CIK: 1095435

Portage Biotech INC. 6-K Filing Summary
FieldDetail
CompanyPortage Biotech INC. (ATON)
Form Type6-K
Filed DateAug 13, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: reporting, foreign-private-issuer

TL;DR

Portage Biotech Inc. filed its August 6-K, confirming it's a foreign private issuer filing 20-F.

AI Summary

Portage Biotech Inc. filed a Form 6-K on August 13, 2024, reporting for the month of August 2024. The company is incorporated in the British Virgin Islands and its principal executive office is located in Tortola. The filing indicates that Portage Biotech Inc. files annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors regarding Portage Biotech Inc.'s reporting status and corporate information.

Risk Assessment

Risk Level: low — This filing is a routine report and does not contain new material financial or operational information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of August 2024.

Where is Portage Biotech Inc. incorporated?

Portage Biotech Inc. is incorporated in the British Virgin Islands.

What is the address of Portage Biotech Inc.'s principal executive office?

The address of the principal executive office is Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110.

Does Portage Biotech Inc. file annual reports under Form 20-F or Form 40-F?

Yes, Portage Biotech Inc. files annual reports under cover of Form 20-F.

Who is the designated company contact person for this filing?

The company contact person is Ian Walters, with a telephone number of 203.221.7378, located at c/o Portage Development Services Inc., 61 Wilton Road, Westport, Connecticut 06880.

Filing Stats: 269 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-08-13 08:00:25

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Portage Biotech Inc. (Registrant) Date: August 13, 2024 /s/ Allan Shaw Allan Shaw Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing